GT Biopharma Inc. Common Stock

GTBPNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
8.61 USD
↗ 2.43 (39.32%)AT CLOSE (11:59 AM EDT)
8.68
↗ 0.07 (0.78%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
8.68
↗ 0.07 (0.78%)
🔴Market: CLOSED

GTBP is currently priced at $8.61. GTBP shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. GTBP is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Sep 11, 2026.

Open?$6.59
High?$8.82
Low?$6.59
Prev. Close?$6.18
Volume?544.3K
Avg. Volume?433.5K
VWAP?$8.06
Rel. Volume?1.26x
Bid / Ask
Bid?$8.66 × 400
Ask?$8.69 × 2.7K
Spread?$0.03
Midpoint?$8.68
Valuation & Ratios
Market Cap?15.5M
Shares Out?N/A
Float?29.5M
Float %?93.5%
P/E Ratio?N/A
P/B Ratio?4.35
EPS?-$18.16
Dividend?1.47%
Ex-Dividend?N/A
News
Profile
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
1
Market Cap
11.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.gtbiopharma.com
Listed
2021-02-11
Address
505 MONTGOMERY STREET
SAN FRANCISCO, CA 94111
Phone: (800) 304-9888
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
59
Piotroski F-Score?0/9Weak
Altman Z-Score?-181.29Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.03%High
Short Interest?3.8M
Days to Cover?10.0
Free Float29.5M
Avg Daily Volume384.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?2.61Strong
Quick Ratio?2.61Strong
Cash Ratio?2.24Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
41
4.35FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-917.9%WEAK▾
ROA?
S&P
3
-566.0%WEAK▾
Cash Flow & Enterprise
FCF?$-14426000
Enterprise Value?$10.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist